2017 | Page 2 of 4 | Certara

White Paper

Drug Asset Evaluation: Increasing “Probability of Success” of a Deal

Certara’s due diligence/asset evaluation teams are comprised of drug development and commercialization experts who advise…

CertaraAugust 24, 2017

Brochure

Investigational Drug Gap Analysis

As the process of drug development has increased in cost and complexity, Certara has developed…

CertaraAugust 14, 2017

Press Coverage

Clinical Pharmacology—The Quarterback of Drug Development

Clinical pharmacology accounts for about 50% of a drug label. Its scope ranges from facilitating…

CertaraAugust 14, 2017

Publication

Parent‐metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients with BRCA 1/2–mutated Cancer or PARP‐sensitive Tumor Types

CertaraAugust 1, 2017

Publication

Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients

CertaraJuly 15, 2017

Publication

Interdisciplinary Pharmacometrics Linking Oseltamivir Pharmacology, Influenza Epidemiology and Health Economics to Inform Antiviral Use in Pandemics

CertaraJuly 1, 2017

Poster

Predicting Diclofenac Systemic and Synovial Fluid Concentrations After Dermal Application Using the Multi-phase Multi-layer MechDermA PBPK Model

CertaraJune 6, 2017

Publication

Time Dependent Pharmacokinetics of Pembrolizumab in Patients with Solid Tumor and Its Correlation with Best Overall Response

CertaraJune 1, 2017

On-Demand Webinar

Obeticholic Acid—From PK Model to Drug Label

Watch this webinar with Jeffrey Edwards to learn how he used physiologic pharmacokinetic modeling to…

CertaraJune 1, 2017

Blog

Mind the Gap: Best Practices in Clinical Pharmacology Gap Analysis

Do you get anxious about taking tests? Many people do because they want to show…

CertaraMay 25, 2017

© 2025 Certara. All Rights Reserved. | Privacy policy